Copyright © 2006, European Society of Cardiology
Myocardial angiogenesis after plasmid or adenoviral VEGF-A165 gene transfer in rat myocardial infarction model
aDepartment of Cardiology, Karolinska University Hospital, M52, S-141 86, Stockholm, Sweden
bDepartment of Thoracic Surgery, Karolinska University Hospital, Stockholm, Sweden
cDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden
* Corresponding author. Tel.: +468 5858 0000; fax: +468 5858 6710. Email address: Christer.Sylven{at}ki.se
Objective: To compare gene transfer of plasmid (P) and adenovirus (Ad) encoding human vascular endothelial growth factor-A165 (hVEGF-A165) angiogenic efficacy and adverse effects as regards apoptosis and ectopic expression of the transgene in a rat myocardial infarction model.
Methods: Myocardial infarction was provoked in Fisher rats. One week later, PhVEGF-A165, PLacZ, AdhVEGF-A165, or AdLacZ was transferred intramyocardially along the border of the myocardial infarction. hVEGF-A expression was detected with ELISA. Myocardial vessel density was analyzed 1 and 4 weeks after gene transfer. Apoptosis was detected by TUNEL staining. Cardiac function was assessed with Tissue Doppler Velocity Imaging.
Results: Although AdhVEGF-A165 had substantially higher myocardial hVEGF-A expression than PhVEGF-A165, AdhVEGF-A165 and PhVEGF-A165 induced angiogenic effects to a similar extent with maintained increased arteriolar density after 4 weeks of gene transfer (p<0.05). The two treatments also improved left ventricular function similarly. Adenoviral gene transfer induced a higher number of TUNEL positive cells than plasmid (p<0.02). Ectopic expression of the transgene was present with both vectors but substantially higher after adenoviral gene transfer.
Conclusions: AdhVEGF-A165 has no obvious angiogenic advantage over PhVEGF-A165 but more side effects at least in a rat myocardial infarction model. This indicates that PhVEGF-A165 might be more applicable for therapeutic angiogenesis than AdhVEGF-A165.
KEYWORDS Angiogenesis; Gene therapy; Infarction; Growth factors; Apoptosis
Time for primary review 28 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Deuse, C. Peter, P. W.M. Fedak, T. Doyle, H. Reichenspurner, W. H. Zimmermann, T. Eschenhagen, W. Stein, J. C. Wu, R. C. Robbins, et al. Hepatocyte Growth Factor or Vascular Endothelial Growth Factor Gene Transfer Maximizes Mesenchymal Stem Cell-Based Myocardial Salvage After Acute Myocardial Infarction Circulation, September 15, 2009; 120(11_suppl_1): S247 - S254. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nikol Viral or non-viral angiogenesis gene transfer-New answers to old questions Cardiovasc Res, February 1, 2007; 73(3): 443 - 445. [Full Text] [PDF] |
||||

